Bria-IMT (SV-BR-1-GM) is BriaCell's investigational allogeneic cell-based cancer immunotherapy regimen, commonly used in combination with a checkpoint inhibitor for advanced metastatic breast cancer. The program is in pivotal randomized Phase 3 development in patients with limited remaining treatment options. It remains unapproved and is being studied in multiple clinical contexts.
BriaCell Therapeutics announced an asset purchase agreement transferring its Soluble CD80 license to majority-owned subsidiary BriaPro, while four abstracts were accepted for presentation at the 2026 AACR Annual Meeting.
The FDA has granted fast track designation to ART6043 plus olaparib for germline BRCA-mutated HER2-negative breast cancer and to BriaCell's Bria-IMT plus immune checkpoint inhibitor for metastatic breast cancer, both addressing significant unmet medical needs.
